New first-in-human trials include Kivu and Menarini projects acting on PKT7 and KIF18A.
ApexOnco Front Page
Recent articles
The project has priority review, but deaths could raise eyebrows.
Keynote-D18 features among the ESMO late-breakers, but IO Biotech can't file.
BNT329 enters the clinic, as do four other new ADCs.
Four more failed tiragolumab trials, including Imbrave-152, will feature.
ALE.P03 is the biotech's third anti-Claudin1, and its second ADC.
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
While InxMed, Takara and L&L have phase 3 plans in lung cancer and beyond.
